查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1471964

卵巢癌药物市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按类型、药物类别、配销通路和地理位置

Ovarian Cancer Drugs Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Drug Class, Distribution Channel, and Geography
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

卵巢癌药物市场规模预计将从2022年的21亿美元增长到2030年的38亿美元。

卵巢癌发生率上升推动对治疗选择的需求推动市场成长

卵巢癌是女性第七大常见癌症，也是继子宫颈癌和子宫内膜癌之后第三大常见妇科恶性肿瘤。根据世界卵巢癌联盟的报告，每年有324,000名女性被诊断出患有卵巢癌，其中207,000人死于该疾病。此外，大多数卵巢癌患者被诊断为晚期（局部晚期或转移性），因为没有可用于早期检测卵巢癌的公共卫生筛检计划。因此，卵巢癌发生率的上升推动了对治疗选择的需求。减瘤手术和铂类化疗相结合的一线治疗是新诊断患有晚期卵巢癌的女性的标准治疗方法。此外，治疗新诊断卵巢癌的突破性选择是经批准的 PARP 抑制剂、olaparib、rucaparib 和 niraparib 等治疗选择。使用 PARP 抑制剂治疗晚期卵巢癌已成为改善该疾病患者临床结果的有效治疗选择。例如，PARP 抑制剂为新诊断的疾病在对第一、第二和第三次铂类化疗完全缓解 (CR) 后提供长期疗效和无恶化存活 (PFS)。因此，卵巢癌治疗药物的重大产品批准将对卵巢癌药物市场规模产生积极影响。

因此，上述因素正在增加对卵巢癌疾病管理药物的需求，促进市场份额的扩大。

卵巢癌市场趋势

联合药物治疗

用于卵巢癌的联合药物治疗将在未来几年显着增长。此外，一些医学研究机构正在开发一种治疗卵巢癌的新型组合药物。例如，2023 年 9 月，皇家马斯登的研究人员宣布了新的药物联合疗法，该疗法已被证明对晚期卵巢癌患者有效。研究人员测试了低度浆液性卵巢癌（LGSOC）的联合药物疗法，这是一种罕见的卵巢癌，对治疗的反应率较差。临床试验「RAMP-201试验」是针对患有LGSOC的患者，使用「avutometinib」药物与另一种药物「defactinib」的组合进行的。中期临床试验结果显示，接受该药物组合治疗的患者中，45% 的肿瘤明显缩小。联合疗法如此令人满意的临床效果，与名为「trametinib」的标靶药物疗法相比，其疗效几乎是后者的两倍，而这种药物在英国上市，反应率仅为 26%。此外，2024年1月，FDA宣布批准「SH-105」作为组合药物用于治疗乳癌和卵巢癌患者。这些临床进展和产品核准是改善女性乳癌和卵巢癌药物取得和管理的重要步骤。这些临床进展为製造商将创新组合产品推向全球市场提供了有利可图的机会。

卵巢癌药物市场，依类型：

依类型划分，卵巢癌药物市场分为上皮性卵巢癌、生殖细胞卵巢癌和间质瘤。上皮性卵巢癌细分市场在 2022 年占据最大的卵巢癌药物市场份额，预计该细分市场在预测期内复合年增长率最高，为 8.2%。

根据英国癌症研究中心的报告，上皮性卵巢癌是最常见的卵巢癌类型。例如，100 个卵巢肿瘤中约有 90 个（90%）是上皮性肿瘤。因此，快速药品核准是治疗上皮性卵巢癌的关键因素，从而对 2020-2030 年预测期内有影响力的细分市场成长负责。此外，患有侵袭性晚期卵巢癌的患者的治疗选择有限。例如，2022 年 11 月，美国食品药物管理局 (FDA) 宣布批准 Elahere Nutrition, Inc. 生产的「mirvetuximab soravtansine-gynx」用于治疗患有上皮性卵巢癌的成年患者。医师建议的「mirvetuximab soravtansine-gynx」剂量为 6mg/kg，每三週一次静脉输注，用于患有上皮性卵巢癌的患者。此外，2024年1月，FDA宣布批准「RC88」的快速通道指定（FTD），RC88是一种间皮素标靶抗体药物偶联物（ADC），用于治疗復发性上皮性卵巢癌患者。

竞争格局及重点企业：

礼来公司、阿斯特捷利康、葛兰素史克、Zielab、ImmunoGen (艾伯维)、GeneTech (罗氏)、Vivesto、Allarity Therapeutics, Inc.、Aeterna Zentaris 和Luye Pharma 是卵巢癌药物市场报告中的知名公司。这些公司专注于新技术、升级现有产品和地理扩张，以满足全球不断增长的消费者需求。

目录

第 1 章：简介

第 2 章：执行摘要

  • 重要见解
  • 市场吸引力分析

第 3 章：研究方法

第 4 章：卵巢癌药物市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链供应商名单

第 5 章：卵巢癌药物市场 - 主要市场动态

  • 主要市场驱动因素
  • 主要市场限制
  • 主要市场机会
  • 未来的趋势
  • 驱动因素和限制因素的影响分析

第 6 章：卵巢癌药物市场 - 全球市场分析

  • 卵巢癌药物 - 全球市场概览
  • 卵巢癌药物 - 全球市场与 2031 年预测

第 7 章：卵巢癌药物市场 - 收入分析 - 按类型，2021-2031

  • 概述
  • 上皮性卵巢癌
  • 生殖细胞卵巢癌
  • 间质瘤

第 8 章：卵巢癌药物市场 - 收入分析 - 按药物类别，2021-2031

  • 概述
  • PARP抑制剂
  • 抗血管新生抑制剂
  • 其他的

第 9 章：卵巢癌药物市场 - 收入分析 - 按配销通路，2021-2031 年

  • 概述
  • 医院药房
  • 零售药局
  • 其他的

第 10 章：卵巢癌药物市场 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

註 - 将为以下提到的地区/国家提供类似的分析

  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与专注

第 13 章：卵巢癌药物市场 - 主要公司概况

  • AbbVie Inc
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Pfizer, Inc.
  • Merck and Co., Inc.
  • ImmunoGen, Inc
  • CLOVIS ONCOLOGY
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline, Plc
  • Amgen Inc

第 14 章：附录

简介目录
Product Code: TIPRE00003750

The ovarian cancer drugs market size is expected to grow from US$ 2.1 billion in 2022 to US$ 3.8 billion by 2030. Factors such as the rising incidence of ovarian cancer propel the demand for therapeutic options thereby responsible for influential ovarian cancer drugs market growth.

Rising Incidence Of Ovarian Cancer Propel The Demand For Therapeutic Options Drives Market Growth

Ovarian cancer is the seventh most common cancer among women and the third most common gynecological malignancy after cervical cancer and endometrial (uterine) cancers. According to the World Ovarian Cancer Coalition report, 324,000 women are diagnosed with ovarian cancer, among which 207,000 die of the disease annually. Further, the majority of patients with ovarian cancer are diagnosed with advanced (locally advanced or metastatic) stage as there is no public health screening program available for early detection of ovarian cancer. Therefore, the rising incidence of ovarian cancer propels the demand for therapeutic options. The first-line therapy with a combination of debulking surgery and platinum-based chemotherapy is standard care for women newly diagnosed with advanced ovarian cancer. Also, the breakthrough options for the management of newly diagnosed ovarian cancer are therapeutic options such as approved PARP inhibitors, olaparib, rucaparib, and niraparib. The use of PARP inhibitors in the management of advanced ovarian cancer has emerged as an effective therapeutic option to improve clinical outcomes for patients suffering from the disease. For example, PARP inhibitors provide long-term efficacy and progression-free survival (PFS) for the newly diagnosed disease following a complete response (CR)to first, second, and third platinum-based chemotherapy. Therefore, significant product approvals for ovarian cancer treatment drugs will positively impact the ovarian cancer drugs market size.

Therefore, the aforementioned factors are increasing the demand for ovarian cancer drugs for disease management, facilitating the expansion of the market share.

Ovarian Cancer Market Trends

Combination Drug Therapy

Combination drug therapy intended for ovarian cancer will grow significantly in the coming years. Also, several medical research institutes are developing a novel combination drug to treat ovarian cancers. For example, in September 2023, Researchers at the Royal Marsden announced new drug combination therapy that proves effective for patients living with advanced ovarian cancer. The researchers tested combination drug therapy for low-grade serous ovarian cancer (LGSOC), which is a rare form of ovarian cancer that has a poor response rate to treatments. The clinical trial "RAMP-201 trial" was conducted by using the "avutometinib" drug with a combination of another drug, namely, "defactinib," for patients suffering from LGSOC. The interim clinical trial results reveal that 45% of the patients treated with the drug combination saw their tumors shrink significantly. Such satisfactory clinical results with combination therapy is almost twice as effective compared to the targeted drug therapy called "trametinib," a drug available in England that has a response rate of only 26%. Further, in January 2024, the FDA announced approval for "SH-105" for the treatment of patients with breast and ovarian cancer as a combination drug. Such clinical advancements and product approvals are important steps to improve access to and administration of drugs that will treat breast and ovarian cancer among women. Such clinical advancements present a lucrative opportunity for the manufacturers to bring innovative combination products into the global market.

Ovarian Cancer Drugs Market, by Type:

By type, the ovarian cancer drugs market is segmented into epithelial ovarian cancer, germ cell ovarian cancer, and stromal tumors. The epithelial ovarian cancer segment held the largest ovarian cancer drugs market share in 2022 and the same segment is anticipated to register the highest CAGR of 8.2% during the forecast period.

According to the Cancer Research UK report, epithelial ovarian cancer is the most common type of ovarian cancer. For example, about 90 out of 100 tumors of the ovary (90%) are epithelial. Therefore, fast drug product approvals is a key factor in treating epithelial ovarian cancer thereby responsible for influential segment growth for the forecast period 2020-2030. Also, patients with aggressive, late-stage ovarian cancer have limited treatment options. For instance, in November 2022, the Food and Drug Administration (FDA) announced approval for "mirvetuximab soravtansine-gynx," manufactured by Elahere ImmunoGen, Inc. for adult patients suffering from epithelial ovarian cancer. The "mirvetuximab soravtansine-gynx" is a recommended dose by the physician of 6mg/kg administered once every three weeks as an IV infusion for epithelial ovarian cancer suffering patients. Additionally, in January 2024, the FDA announced approval for fast-track designation (FTD) for "RC88," a mesothelin-targeting antibody-drug conjugate (ADC) for the treatment of patients with recurrent epithelial ovarian cancer.

Competitive Landscape and Key Companies:

Elli Lilly, AstraZeneca, GSK, Zielab, ImmunoGen (AbbVie), GeneTech (Roche), Vivesto, Allarity Therapeutics, Inc., Aeterna Zentaris, and Luye Pharma are the prominent companies in the ovarian cancer drugs market report. These companies focus on new technologies, upgrading existing products, and geographic expansions to meet the growing consumer demand worldwide.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Ovarian Cancer Drugs Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Ovarian Cancer Drugs Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Ovarian Cancer Drugs Market - Global Market Analysis

  • 6.1 Ovarian Cancer Drugs - Global Market Overview
  • 6.2 Ovarian Cancer Drugs - Global Market and Forecast to 2031

7. Ovarian Cancer Drugs Market - Revenue Analysis (USD Million) - By Type, 2021-2031

  • 7.1 Overview
  • 7.2 Epithelial Ovarian Cancer
  • 7.3 Germ Cell Ovarian Cancer
  • 7.4 Stromal Tumors

8. Ovarian Cancer Drugs Market - Revenue Analysis (USD Million) - By Drug Class, 2021-2031

  • 8.1 Overview
  • 8.2 PARP Inhibitors
  • 8.3 Anti-Angiogenesis Inhibitors
  • 8.4 Others

9. Ovarian Cancer Drugs Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Others

10. Ovarian Cancer Drugs Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Ovarian Cancer Drugs Market Overview
    • 10.1.2 North America Ovarian Cancer Drugs Market Revenue and Forecasts to 2031
    • 10.1.3 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Type
    • 10.1.4 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Drug Class
    • 10.1.5 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 10.1.6 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Ovarian Cancer Drugs Market
        • 10.1.6.1.1 United States Ovarian Cancer Drugs Market, by Type
        • 10.1.6.1.2 United States Ovarian Cancer Drugs Market, by Drug Class
        • 10.1.6.1.3 United States Ovarian Cancer Drugs Market, by Distribution Channel
      • 10.1.6.2 Canada Ovarian Cancer Drugs Market
        • 10.1.6.2.1 Canada Ovarian Cancer Drugs Market, by Type
        • 10.1.6.2.2 Canada Ovarian Cancer Drugs Market, by Drug Class
        • 10.1.6.2.3 Canada Ovarian Cancer Drugs Market, by Distribution Channel
      • 10.1.6.3 Mexico Ovarian Cancer Drugs Market
        • 10.1.6.3.1 Mexico Ovarian Cancer Drugs Market, by Type
        • 10.1.6.3.2 Mexico Ovarian Cancer Drugs Market, by Drug Class
        • 10.1.6.3.3 Mexico Ovarian Cancer Drugs Market, by Distribution Channel

Note - Similar analysis would be provided for below mentioned regions/countries

  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Ovarian Cancer Drugs Market - Key Company Profiles

  • 13.1 AbbVie Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 13.2 AstraZeneca
  • 13.3 F. Hoffmann-La Roche Ltd
  • 13.4 Pfizer, Inc.
  • 13.5 Merck and Co., Inc.
  • 13.6 ImmunoGen, Inc
  • 13.7 CLOVIS ONCOLOGY
  • 13.8 Boehringer Ingelheim International GmbH
  • 13.9 GlaxoSmithKline, Plc
  • 13.10 Amgen Inc

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud